In conclusion, the involvement of bone as a major target of inflammation in RA and AS raises many questions [ 10, 181- 184], opening perspectives for further research in the understanding and treatment of the complex bone disease component of RA and AS.
They involved the implant of both human tumor cells and human bone as a metastatic target in non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice, allowing the study of the cell-cell interactions within all human tissues at the target site.
Once the alignment had been completed, both talus bones were imported into Geomagic Qualify 2013 (Geomagic®), and a deviation analysis was performed, in which the right talus bone was used as the reference model, while the left talus bone was used as a target model.
In both rheumatoid arthritis (RA) and ankylosing spondylitis (AS), bone is a target of inflammation.
Therefore it may also have implications in bone pathophysiology and as a target for further evaluation in osteosarcoma.
There is an increased level of interest in subchondral bone as a therapeutic OA target, and, in particular, the possibility that drugs affecting bone metabolism might alter the progression of knee and hip OA.
In addition, a high level of SDF-1 was noted in bone as well as in all target organs for breast-cancer metastasis and, in Nude mice, a neutralising anti-CXCR-4 antibody induces a significant inhibition of breast-cancer metastasis in vivo, indicating a major role of the SDF-1/CXCR-4 pathway in the metastatic process.
In summary, we were able to use tissue-engineered bone marrow to serve as a target or "trap" for metastasizing cancer cells.
In the last decade, canonical Wnt signaling has become a central focus in studying the promotion of healthy bone tissue as well as a target for potential therapeutic applications.
